ARDX Share Price Performance
US$5.98
0.26 (4.55%)
48.4% undervalued intrinsic discount
US$11.60
Fair Value
Price US$5.98
AnalystConsensusTarget US$11.60
AnalystHighTarget US$15.00
AnalystLowTarget US$8.00
Fair ValueUS$11.60
Share Pricen/a
Ardelyx, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 115 Fair Values set on narratives written by author
ARDX Community Narratives
AN
Fair Value US$11.6 48.4% undervalued intrinsic discount
Global Healthcare And Aging Trends Will Unleash Market Opportunity
0users have liked this narrative
0users have commented on this narrative
60users have followed this narrative
AN
Fair Value US$15 60.1% undervalued intrinsic discount
Accelerating CKD And IBS-C Demand Will Transform Treatment Landscape
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$8 25.3% undervalued intrinsic discount
Pricing And Regulation Risks Will Undercut Revenue Yet Yield Recovery
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Global Healthcare And Aging Trends Will Unleash Market Opportunity
Key Takeaways Expanding markets, better market access, and prescription growth are accelerating adoption of core therapies, supporting sustained revenue and margin improvement. International partnerships and new indications diversify revenue streams, mitigate risks, and enhance long-term earnings stability.Read more
0users have liked this narrative
0users have commented on this narrative
60users have followed this narrative
AN
US$11.6
48.4% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
23.1% p.a.
Profit Margin
32.73%
Future PE
15.16x
Price in 2028
US$14.32
Pricing And Regulation Risks Will Undercut Revenue Yet Yield Recovery
Key Takeaways Heavy reliance on a few key products leaves Ardelyx exposed to reimbursement challenges, pricing pressures, and strong competition in core therapeutic areas. Expanding regulatory scrutiny, rising compliance and R&D costs, and restricted drug market access threaten net margins and delay sustainable profitability.Read more
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$8
25.3% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
10.85% p.a.
Profit Margin
10.93%
Future PE
42.98x
Price in 2028
US$9.74
Accelerating CKD And IBS-C Demand Will Transform Treatment Landscape
Key Takeaways Surging product sales, prescriber engagement, and market expansion point to potential revenue and margin growth exceeding current projections for both major drugs. Operational leverage, global partnerships, and a strengthened balance sheet offer increased margin expansion and recurring revenue opportunities, fueling future enterprise value.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$15
60.1% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
30.18% p.a.
Profit Margin
36.64%
Future PE
14.84x
Price in 2028
US$18.25
Trending Discussion
Recently Updated Narratives
AN
ARDX: Commercial Execution Will Drive Shares Higher Under New Leadership
Fair Value: US$11.6 48.4% undervalued intrinsic discount
60 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Pricing And Regulation Risks Will Undercut Revenue Yet Yield Recovery
Fair Value: US$8 25.3% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Accelerating CKD And IBS-C Demand Will Transform Treatment Landscape
Fair Value: US$15 60.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ardelyx, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.23
- 72.56%
- -14.20%
- 149.6%
About ARDX
- Founded
- 2007
- Employees
- 395
- CEO
- WebsiteView website
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
